{"ticker": {"uuid": "d369e0c2-e198-4282-b413-d8e0b35bb453", "symbol": "SCYX", "name": "Scynexis Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "FEDERATED HERMES, INC. Acquires 55,207 Shares of SCYNEXIS Inc", "summary": "FEDERATED HERMES, INC. recently acquired 55,207 shares of SCYNEXIS Inc for $4.07 per share, a move that now accounts for 4.45% of its portfolio. SCYNEXIS Inc, a drug development company focusing on anti-infectives, has a market cap of $48.958 million, but its financial metrics an", "url": "https://www.gurufocus.com/news/8958928/federated-hermes-inc-acquires-55207-shares-of-scynexis-inc?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-15T10:12:19", "published_display": "15 Jul 2026 10:12", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Federated Hermes (SCYX) files 13G/A showing 55,207 shares (4.45%)", "summary": "Federated Hermes, Inc. and related entities have filed an amended Schedule 13G/A, disclosing a passive stake of 55,207 shares in SCYNEXIS (SCYX), which represents 4.45% of the common stock. This filing indicates a passive investment intent and includes a Rule 13d-4 disclaimer, st", "url": "https://www.stocktitan.net/sec-filings/SCYX/schedule-13g-a-scynexis-inc-amended-passive-investment-disclosure-9ec28ef54851.html", "source_name": "Stock Titan", "published_at": "2026-07-08T12:11:19", "published_display": "08 Jul 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of SCYNEXIS, Inc. \u2013 NASDAQ:SCYX", "summary": "This page from TradingView provides financial information for SCYNEXIS, Inc. (NASDAQ: SCYX), specifically focusing on its enterprise value to EBIT forward. It displays the company's financials under the Pharmaceuticals: Major category in the US stock market, indicating it's a dat", "url": "https://www.tradingview.com/symbols/NASDAQ-SCYX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T20:41:33", "published_display": "06 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scynexis Deadline Alert", "summary": "Faruqi & Faruqi, LLP is investigating potential claims against SCYNEXIS, Inc. (NASDAQ: SCYX) and reminds investors of the January 8, 2024 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges that Scynexis made false or misl", "url": "https://www.newsfilecorp.com/release/191467/Scynexis-Deadline-Alert?lang=fr", "source_name": "TMX Newsfile", "published_at": "2026-07-06T18:41:02", "published_display": "06 Jul 2026 18:41", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of SCYNEXIS, Inc. \u2013 FWB:135", "summary": "The article provides a title for financial data on SCYNEXIS, Inc. (FWB:135) concerning its Enterprise Value to EBIT forward metric. The content indicates that this information would be found under the Financials section of the company's profile on TradingView. However, the specif", "url": "https://www.tradingview.com/symbols/FWB-135/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T19:11:21", "published_display": "05 Jul 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS (NASDAQ:SCYX) Is In A Strong Position To Grow Its Business", "summary": "SCYNEXIS (SCYX) is assessed to be in a strong financial position due to a low cash burn rate and significant revenue growth. The company has a long cash runway of many years, with its cash burn down 78% and operating revenue up 674% over the last year. Analysts believe SCYNEXIS c", "url": "https://www.sahmcapital.com/news/content/scynexis-nasdaqscyx-is-in-a-strong-position-to-grow-its-business-2026-07-03", "source_name": "Sahm", "published_at": "2026-07-03T07:11:22", "published_display": "03 Jul 2026 07:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form DEF 14A Scynexis Inc For: 2 July By Investing.com", "summary": "This article announces the filing of Form DEF 14A by Scynexis Inc. on July 2nd. It's a brief financial news update from Investing.com, noting the date of the filing. The article also includes stock market data and other news headlines.", "url": "https://ng.investing.com/news/stock-market-news/form-def-14a-scynexis-inc-for-2-july-93CH-2585026", "source_name": "Investing.com Nigeria", "published_at": "2026-07-02T21:20:00", "published_display": "02 Jul 2026 21:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS (SCYX) director Armando Anido granted stock units and options", "summary": "SCYNEXIS Inc. director Armando Anido was granted 2,875 shares of Common Stock as restricted stock units and 2,875 stock options, both at no cost. The options have an exercise price of $3.85 and expire on June 25, 2036. Both the restricted stock units and options vest 100% on the ", "url": "https://www.stocktitan.net/sec-filings/SCYX/form-4-scynexis-inc-insider-trading-activity-cd7d0ddd7d4b.html", "source_name": "Stock Titan", "published_at": "2026-07-01T07:10:30", "published_display": "01 Jul 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Scynexis Inc For: 30 June By Investing.com", "summary": "This article from Investing.com announces the filing of a Form 4 for Scynexis Inc. as of June 30, 2026. Form 4 filings report changes in beneficial ownership of a company's securities by insiders. The article provides the title and links to current market data for various indices", "url": "https://ng.investing.com/news/stock-market-news/form-4-scynexis-inc-for-30-june-93CH-2580771", "source_name": "Investing.com Nigeria", "published_at": "2026-07-01T06:39:15", "published_display": "01 Jul 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS (SCYX) director Ann Hanham receives stock and option grants", "summary": "SCYNEXIS director Ann Hanham received new equity awards, including 2,875 shares of common stock at no cost and 2,875 stock options with a strike price of $3.85 per share. Both the restricted stock units and stock options will vest in full on the first anniversary of the grant dat", "url": "https://www.stocktitan.net/sec-filings/SCYX/form-4-scynexis-inc-insider-trading-activity-0f9cba20cd22.html", "source_name": "Stock Titan", "published_at": "2026-07-01T05:10:30", "published_display": "01 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS (NASDAQ: SCYX) director gets RSU and option awards", "summary": "SCYNEXIS director Guy Macdonald was granted 2,875 restricted stock units (RSUs) and a stock option for 2,875 shares at an exercise price of $3.85 per share on June 26, 2026. Both awards vest fully on the first anniversary of the grant, contingent on his continued service as a non", "url": "https://www.stocktitan.net/sec-filings/SCYX/form-4-scynexis-inc-insider-trading-activity-4fce9bdd9d39.html", "source_name": "Stock Titan", "published_at": "2026-07-01T05:10:30", "published_display": "01 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of SCYNEXIS, Inc. \u2013 FWB:135", "summary": "The article \"Enterprise value to revenue forward of SCYNEXIS, Inc. \u2013 FWB:135\" focuses on the financial metric of enterprise value to revenue for SCYNEXIS, Inc., trading on the Frankfurt Stock Exchange under ticker 135. It appears to be a financial data page rather than a detailed", "url": "https://www.tradingview.com/symbols/FWB-135/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T05:10:30", "published_display": "01 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS (SCYX) director receives new stock and option awards", "summary": "SCYNEXIS director David C. Hastings was granted 2,875 shares of common stock and stock options for 2,875 shares with an exercise price of $3.85 per share. Both awards vest 100% on the first anniversary of the June 26, 2026 grant date, provided he continues as a non-employee direc", "url": "https://www.stocktitan.net/sec-filings/SCYX/form-4-scynexis-inc-insider-trading-activity-36e3fc3df116.html", "source_name": "Stock Titan", "published_at": "2026-07-01T05:10:30", "published_display": "01 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS (SCYX) director receives new RSU and stock option grants", "summary": "SCYNEXIS director Brian Philippe Tinmouth was granted 2,875 restricted stock units and a stock option for 2,875 shares, both vesting one year from June 26, 2026, provided he continues as a non-employee director. The stock option has an exercise price of $3.85 per share and expire", "url": "https://www.stocktitan.net/sec-filings/SCYX/form-4-scynexis-inc-insider-trading-activity-ea56421e05a1.html", "source_name": "Stock Titan", "published_at": "2026-07-01T04:10:30", "published_display": "01 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)", "summary": "SCYNEXIS, Inc. has initiated a Phase 1 study for SCY-770, a novel AMPK activator, targeting Autosomal Dominant Polycystic Kidney Disease (ADPKD). This study aims to optimize dosing and pharmacokinetics to support a Phase 2 proof-of-concept study expected in Q4 2026. SCY-770 has s", "url": "https://www.manilatimes.net/2026/06/30/tmt-newswire/globenewswire/scynexis-initiates-phase-1-study-of-scy-770-a-novel-ampk-activator-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd/2375739", "source_name": "The Manila Times", "published_at": "2026-06-30T12:09:58", "published_display": "30 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast for SCYNEXIS, Inc. (SCYX) stock, including analyst price targets and current financial data. It notes that three analysts have provided 1-year price forecasts, with estimates ranging from $24.00 to $44.64. The company's current stock price, market ", "url": "https://www.tradingview.com/symbols/NASDAQ-SCYX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-30T10:10:12", "published_display": "30 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of SCYNEXIS, Inc. \u2013 NASDAQ:SCYX", "summary": "This article provides financial data for SCYNEXIS, Inc. (NASDAQ: SCYX), specifically focusing on its price-to-sales forward metric. It details the stock's status as market closed with no trades and lists various services that provide market and reference data for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-SCYX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T07:41:02", "published_display": "30 Jun 2026 07:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of SCYNEXIS, Inc. \u2013 NASDAQ:SCYX", "summary": "The article provides a snapshot of SCYNEXIS, Inc. (NASDAQ: SCYX) on TradingView, focusing on its \"Price to book forward\" metric. It lists various sections available on the platform for the company, including financials, news, and technical analysis, but does not provide specific ", "url": "https://www.tradingview.com/symbols/NASDAQ-SCYX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T04:41:33", "published_display": "30 Jun 2026 04:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of SCYNEXIS, Inc. \u2013 GETTEX:135", "summary": "This article provides financial information for SCYNEXIS, Inc. (GETTEX:135), specifically focusing on its enterprise value to revenue forward metric. The data is presented within the context of the Gettex exchange and is sourced from various financial data providers.", "url": "https://www.tradingview.com/symbols/GETTEX-135/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T23:41:34", "published_display": "29 Jun 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of SCYNEXIS, Inc. \u2013 NASDAQ:SCYX", "summary": "The article displays the enterprise value to EBITDA forward for SCYNEXIS, Inc. (NASDAQ: SCYX) on the TradingView platform. It shows the stock information and indicates that the market is closed with no trades. The article is a snapshot from a financial platform, providing basic s", "url": "https://www.tradingview.com/symbols/NASDAQ-SCYX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T05:40:14", "published_display": "29 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of SCYNEXIS, Inc. \u2013 GETTEX:135", "summary": "The article focuses on the \"Price to sales forward\" metric for SCYNEXIS, Inc. (GETTEX:135). It appears to be a financial data point provided by TradingView, detailing a specific period, its value, and percentage change. The content itself seems to be a placeholder for financial d", "url": "https://www.tradingview.com/symbols/GETTEX-135/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T01:39:04", "published_display": "29 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS (SCYX) expands authorized stock and registers 87M shares for resale", "summary": "SCYNEXIS, Inc. (SCYX) has increased its authorized stock from 23,750,000 to 65,000,000 shares, with common stock specifically rising from 18,750,000 to 60,000,000 shares, following stockholder approval at its June 25, 2026 annual meeting. The company also registered up to 87,000,", "url": "https://www.stocktitan.net/sec-filings/SCYX/8-k-scynexis-inc-reports-material-event-663aabe53575.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:10:23", "published_display": "26 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS, Inc. Actuals & Estimates (NASDAQ:SCYX)", "summary": "This article provides a comprehensive overview of SCYNEXIS, Inc. (NASDAQ: SCYX), detailing its current stock price, historical performance, analyst forecasts, and financial data. It includes information on market capitalization, volatility, earnings reports, revenue, net income, ", "url": "https://www.tradingview.com/symbols/NASDAQ-SCYX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-24T10:10:46", "published_display": "24 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS Inc (SCYX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for SCYNEXIS Inc (SCYX), highlighting its current earnings forecast score, analyst ratings, and price targets. It notes an average price target of $4.00 and that analysts generally recommend a \"Buy\" trend for the stock, based on 3 analys", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scyx/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T12:09:53", "published_display": "18 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS Inc (SCYX) Institutional Confidence", "summary": "This article analyzes the institutional confidence in SCYNEXIS Inc (SCYX), reporting its current institutional shareholding score as 3.00, which ranks 94th out of 157 in the Pharmaceuticals industry. The institutional shareholding proportion is 25.24%, a 22.57% decrease quarter-o", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scyx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:10", "published_display": "18 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS Inc (SCYX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "SCYNEXIS Inc (SCYX) has a strong financial score of 9.27, ranking 5th in the Pharmaceuticals industry, indicating robust financial health and high operating efficiency. Despite this, its latest quarterly revenue saw a 100% year-over-year decrease, and net profit fell by 295.08%. ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scyx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:10", "published_display": "18 Jun 2026 10:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS Inc (SCYX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of SCYNEXIS Inc (SCYX), detailing its current stock price momentum, support and resistance levels, and insights from various technical indicators and moving averages. While the stock is currently trading within a range, technical signals", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scyx/technical", "source_name": "TradingKey", "published_at": "2026-06-18T09:40:09", "published_display": "18 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS Inc (SCYX) Valuation: PE, PB & Fair Value Analysis", "summary": "SCYNEXIS Inc (SCYX) currently holds a valuation score of 9.33, ranking 32nd out of 157 companies in the Pharmaceuticals industry. The company's P/E ratio is -7.89, which is significantly below its recent high but above its recent low. Key valuation metrics such as P/B, P/S, and P", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scyx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T09:40:09", "published_display": "18 Jun 2026 09:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS Announces One-for-Eight Reverse Stock Split", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/scynexis-announces-one-eight-reverse-201500685.html", "source_name": "GlobeNewswire", "published_at": "2026-05-22T20:15:00+00:00", "published_display": "22 May 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS (SCYX) Announces 1-for-8 Reverse Stock Split to Meet Na", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxQVWNRSmk5MFVjMklNLW81aDkyM2tpejJxQV92TE9MQ3ByZzR4dFZ2dFFybFhOWW5hZmtmZDVFOTVNSEpLdDhTaERqbXNTaUViQml3eVpOMUFzNGdjZWZSUXJoakdrTUZvRXpub0RIcXZ2cHRoaC1OS1JlR2E0UE0yUk0yd3U5dUZnV3RBOUV6VWdrc1l2ODNHcGpTX19PLXRrVkVaT3M5ZHphdFBscGVsUmZjOHhzc254MlA1QklySlBnc3l6MnEyeTM4ZmE0d01LUzFiSG1JVlZHYXh2?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS announces 1-for-8 reverse stock split effective May 29", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQM2YxbzV3eWZEdGdoaHdxNi1MQnV0OGl4TWNMUkg1LTdHTy1OSHNuLVQ5WHBPd3dwSHNFYnBNd0V0R2EwMUYxUDNIbjdGejI2Qi1lVEJ2N3pieWc1ZmZ0NVlQc2liZHYyTGwtT1JmUm5oZlZxdW1DRTB1Y0hwRnVER0xackVaQ28yeFItbXhaNFlsNktxM3hscU10bnM0XzBIcmJOZU9FX3VWY1BIei1wUGIxRmptVElzQXc?oc=5", "source_name": "Investing.com", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scynexis stock falls 7% on reverse stock split announcement", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNZWtDWExId0RSWnhGT3hRS2FiNHJZYk10VlladFBrcG5xUmYwSGhieDlWdXBqNkpxd3hOTGlfT1BhOXprbFpWNjUyNlpxeVUwZVotR0l1MllRY3Y0QU1idVJ3U3U4MG5vbTJ2UmRwVEE3M1IwUXZZYnRFRGNmNWVDTEFhVFp5R3Q2dWd0YlM1Z0JUTTFad1ZEVG5WYUlrdVFSUEt0MXE3bHI5OTlBWl9Ib2FjOWx6R19oV0c4Sw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scynexis: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/scynexis-q1-earnings-snapshot-204354134.html", "source_name": "Associated Press", "published_at": "2026-05-11T20:43:54+00:00", "published_display": "11 May 2026 20:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/scynexis-reports-first-quarter-2026-202300240.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T20:23:00+00:00", "published_display": "11 May 2026 20:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/scynexis-announces-inducement-awards-under-011500593.html", "source_name": "GlobeNewswire", "published_at": "2026-05-07T01:15:00+00:00", "published_display": "07 May 2026 01:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scynexis CEO Angulo Gonzalez buys $100k in shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQcnZlZUhFeFZ5YkgzM0pYNzhvSmFNWTJJWTUwQmVXSnV4ZzhyTEpoRy1hRTRqaFNyQkdObk1zMmR5elVpZWhWNUFGNG9ZSzFhMDNRdTZKdHlFS2JiX0xCTHU1OHBXdF9aTVFDUzVia1pqa2NlSFdOOXlXVFRDYWpmWnV2N0o1U1VKTlpaN0UteEd0bXZLR2l0QlczVzJlRTJKUnhvdTNocjBCMmYxUnA1VmFjaw?oc=5", "source_name": "Investing.com", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scynexis In Spotlight After Poxel Deal, $40 Million Private Placement \u2013 SCYX Stock Climbs 2% Pre-Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQWWhpTzBqRF9WeWZZYUt1Sy0tVXlUakRtM2ZiTHhNWDhvTVRIaGtlWDQyTnQyalJRYnJ2Z2MxNWM0OFFiVExodU9XMjRHdUZyRS1hSDQwWE01ckhrUDFiWG9zaG5XazdrSGs5R3djWHVnaGJ3bG9EV1NhZkVucndjZ3BGMDlUeklrLVJkdmdGMWkzSzdjM0lMcGgybjI2NU5YR0NrellZa3dKT0U?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS acquires SCY-770 for rare kidney disease treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNd0RMN2dsOEZhU1hNOTgxenhQV0NMNUVuNXVPcHM1LWtoUWxDVzVtNzh1Q2JBc1pUa0dad2ZiNHRZWXBWYlA2b0VaQ2V6eFN5Q0JPUXdmdWxqX2Vlcmpwa0xuNWZON1NjNktVdmxMQnhHdEVhYVNTMlE5VUpEVDlrTFZmczF0dmJhRHZtUFB5NlFmb0RHVlVBVkV1N1lEVFJNTDRBX2dTZUtIQ0RNc1hsQWkzNExRQQ?oc=5", "source_name": "Investing.com", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS Completes BREXAFEMME NDA Transfer to GSK, Positioning for Future Milestones and Royalties", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxQTWRMVnZRQXpxNEx1ZEgwR25MWm5RemUxSVJQMloxaVBvRU5yRHdFblJrNVBNTFZudW1jNnE4U0tPUWNxb3g4WlhSLUtBVTd5c0YzeHBNMndEQVhycVBEeGNneTRLazlmczFzc3RiN2R2alFpY3FSTS12b2FERWQxVkRfNXJEaXdLSWtTVnNIQ1pmMkJCVm1kbUVSY2RhRUZZLXZCdHE0SFBuVFRoQVF3cHBOT1AzUFdEbk9sdU9mYkU5UzhQS1pRTm96aEpMUQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-11-19T08:00:00+00:00", "published_display": "19 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're A Bit Worried About SCYNEXIS' (NASDAQ:SCYX) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE5oQUg0d1gzQnhiRm5LZjVWZENVVEMyckFySjlFQUFHUk5mYWhJN01XMEM1TFhsUEpnZHE5bVNxQzRQQlFpbE4yc1RDSVN6dGpDdDR2bzJyenByMlFBWk9CZXRqRFV6UTBkbVFYNzVCdVBmMlJXWjZ3U21sQjM?oc=5", "source_name": "Market source", "published_at": "2025-11-10T08:00:00+00:00", "published_display": "10 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS Secures $24.8 Million Payment from GSK and Advances SCY-247 Development Plans Amid Phase 3 Study Termination", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOY0UxRFRyVm1wRTMwWk4zOXFibVBhZmpDaVp3WVNEQzZwbXFWR2xzV19VV3NNVXlHWnRRcjJtUk1vUC1qcnBuUGNYWkhvQjRlVXBlazlQRVV0aTZhWDY2RFJ3X01nTktPX0VrZm1Ienk5V196aXpnbFV2aDZRRHZVQnA5RG5WWV9yVlp4WkJzb080bk5fMEU0cDkydzZpcnR4NkNCRERCdzZXWWZMTUIzREZ5T2ZkQTdfLUZ4Y3l0MXpMWkRxWE84UEdNQkVRUDRLYUdidHNPb3E4Zjk0a0VGTWFVTGFkRms?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-11-05T08:00:00+00:00", "published_display": "05 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYX Stock Price and Chart \u2014 NASDAQ:SCYX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1wbnRQcXhNUE84U0pLV2lGZ3hJbkNqUzBnYi1meUdfWVRpUFp0SkZ4ejV5dWs5SmhZSnllZ1k0NGM4ckVQQlFLXy1nbmVoQXRINzRaNWp4SFptQnFt?oc=5", "source_name": "TradingView", "published_at": "2017-07-21T03:30:44+00:00", "published_display": "21 Jul 2017 03:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS (SCYX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1WYWZ5RE1ERFAxcVpib01XNUdpZE54VjItR1lwSWNTYzRMOV9jaWJhOHlGWnlsdGlRREJ2MnJCSExYNzU1TTd6QnEwSmNPbDFxRmtlYkxMNmhXZw?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-12T07:14:17+00:00", "published_display": "12 Aug 2016 07:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "FEDERATED HERMES, INC. Acquires 55,207 Shares of SCYNEXIS Inc", "summary": "FEDERATED HERMES, INC. recently acquired 55,207 shares of SCYNEXIS Inc for $4.07 per share, a move that now accounts for 4.45% of its portfolio. SCYNEXIS Inc, a drug development company focusing on anti-infectives, has a market cap of $48.958 million, but its financial metrics an", "url": "https://www.gurufocus.com/news/8958928/federated-hermes-inc-acquires-55207-shares-of-scynexis-inc?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-15T10:12:19", "published_display": "15 Jul 2026 10:12", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Federated Hermes (SCYX) files 13G/A showing 55,207 shares (4.45%)", "summary": "Federated Hermes, Inc. and related entities have filed an amended Schedule 13G/A, disclosing a passive stake of 55,207 shares in SCYNEXIS (SCYX), which represents 4.45% of the common stock. This filing indicates a passive investment intent and includes a Rule 13d-4 disclaimer, st", "url": "https://www.stocktitan.net/sec-filings/SCYX/schedule-13g-a-scynexis-inc-amended-passive-investment-disclosure-9ec28ef54851.html", "source_name": "Stock Titan", "published_at": "2026-07-08T12:11:19", "published_display": "08 Jul 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of SCYNEXIS, Inc. \u2013 NASDAQ:SCYX", "summary": "This page from TradingView provides financial information for SCYNEXIS, Inc. (NASDAQ: SCYX), specifically focusing on its enterprise value to EBIT forward. It displays the company's financials under the Pharmaceuticals: Major category in the US stock market, indicating it's a dat", "url": "https://www.tradingview.com/symbols/NASDAQ-SCYX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T20:41:33", "published_display": "06 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scynexis Deadline Alert", "summary": "Faruqi & Faruqi, LLP is investigating potential claims against SCYNEXIS, Inc. (NASDAQ: SCYX) and reminds investors of the January 8, 2024 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges that Scynexis made false or misl", "url": "https://www.newsfilecorp.com/release/191467/Scynexis-Deadline-Alert?lang=fr", "source_name": "TMX Newsfile", "published_at": "2026-07-06T18:41:02", "published_display": "06 Jul 2026 18:41", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of SCYNEXIS, Inc. \u2013 FWB:135", "summary": "The article provides a title for financial data on SCYNEXIS, Inc. (FWB:135) concerning its Enterprise Value to EBIT forward metric. The content indicates that this information would be found under the Financials section of the company's profile on TradingView. However, the specif", "url": "https://www.tradingview.com/symbols/FWB-135/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T19:11:21", "published_display": "05 Jul 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS (NASDAQ:SCYX) Is In A Strong Position To Grow Its Business", "summary": "SCYNEXIS (SCYX) is assessed to be in a strong financial position due to a low cash burn rate and significant revenue growth. The company has a long cash runway of many years, with its cash burn down 78% and operating revenue up 674% over the last year. Analysts believe SCYNEXIS c", "url": "https://www.sahmcapital.com/news/content/scynexis-nasdaqscyx-is-in-a-strong-position-to-grow-its-business-2026-07-03", "source_name": "Sahm", "published_at": "2026-07-03T07:11:22", "published_display": "03 Jul 2026 07:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form DEF 14A Scynexis Inc For: 2 July By Investing.com", "summary": "This article announces the filing of Form DEF 14A by Scynexis Inc. on July 2nd. It's a brief financial news update from Investing.com, noting the date of the filing. The article also includes stock market data and other news headlines.", "url": "https://ng.investing.com/news/stock-market-news/form-def-14a-scynexis-inc-for-2-july-93CH-2585026", "source_name": "Investing.com Nigeria", "published_at": "2026-07-02T21:20:00", "published_display": "02 Jul 2026 21:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS (SCYX) director Armando Anido granted stock units and options", "summary": "SCYNEXIS Inc. director Armando Anido was granted 2,875 shares of Common Stock as restricted stock units and 2,875 stock options, both at no cost. The options have an exercise price of $3.85 and expire on June 25, 2036. Both the restricted stock units and options vest 100% on the ", "url": "https://www.stocktitan.net/sec-filings/SCYX/form-4-scynexis-inc-insider-trading-activity-cd7d0ddd7d4b.html", "source_name": "Stock Titan", "published_at": "2026-07-01T07:10:30", "published_display": "01 Jul 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Scynexis Inc For: 30 June By Investing.com", "summary": "This article from Investing.com announces the filing of a Form 4 for Scynexis Inc. as of June 30, 2026. Form 4 filings report changes in beneficial ownership of a company's securities by insiders. The article provides the title and links to current market data for various indices", "url": "https://ng.investing.com/news/stock-market-news/form-4-scynexis-inc-for-30-june-93CH-2580771", "source_name": "Investing.com Nigeria", "published_at": "2026-07-01T06:39:15", "published_display": "01 Jul 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS (SCYX) director Ann Hanham receives stock and option grants", "summary": "SCYNEXIS director Ann Hanham received new equity awards, including 2,875 shares of common stock at no cost and 2,875 stock options with a strike price of $3.85 per share. Both the restricted stock units and stock options will vest in full on the first anniversary of the grant dat", "url": "https://www.stocktitan.net/sec-filings/SCYX/form-4-scynexis-inc-insider-trading-activity-0f9cba20cd22.html", "source_name": "Stock Titan", "published_at": "2026-07-01T05:10:30", "published_display": "01 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS (NASDAQ: SCYX) director gets RSU and option awards", "summary": "SCYNEXIS director Guy Macdonald was granted 2,875 restricted stock units (RSUs) and a stock option for 2,875 shares at an exercise price of $3.85 per share on June 26, 2026. Both awards vest fully on the first anniversary of the grant, contingent on his continued service as a non", "url": "https://www.stocktitan.net/sec-filings/SCYX/form-4-scynexis-inc-insider-trading-activity-4fce9bdd9d39.html", "source_name": "Stock Titan", "published_at": "2026-07-01T05:10:30", "published_display": "01 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of SCYNEXIS, Inc. \u2013 FWB:135", "summary": "The article \"Enterprise value to revenue forward of SCYNEXIS, Inc. \u2013 FWB:135\" focuses on the financial metric of enterprise value to revenue for SCYNEXIS, Inc., trading on the Frankfurt Stock Exchange under ticker 135. It appears to be a financial data page rather than a detailed", "url": "https://www.tradingview.com/symbols/FWB-135/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T05:10:30", "published_display": "01 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS (SCYX) director receives new stock and option awards", "summary": "SCYNEXIS director David C. Hastings was granted 2,875 shares of common stock and stock options for 2,875 shares with an exercise price of $3.85 per share. Both awards vest 100% on the first anniversary of the June 26, 2026 grant date, provided he continues as a non-employee direc", "url": "https://www.stocktitan.net/sec-filings/SCYX/form-4-scynexis-inc-insider-trading-activity-36e3fc3df116.html", "source_name": "Stock Titan", "published_at": "2026-07-01T05:10:30", "published_display": "01 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS (SCYX) director receives new RSU and stock option grants", "summary": "SCYNEXIS director Brian Philippe Tinmouth was granted 2,875 restricted stock units and a stock option for 2,875 shares, both vesting one year from June 26, 2026, provided he continues as a non-employee director. The stock option has an exercise price of $3.85 per share and expire", "url": "https://www.stocktitan.net/sec-filings/SCYX/form-4-scynexis-inc-insider-trading-activity-ea56421e05a1.html", "source_name": "Stock Titan", "published_at": "2026-07-01T04:10:30", "published_display": "01 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)", "summary": "SCYNEXIS, Inc. has initiated a Phase 1 study for SCY-770, a novel AMPK activator, targeting Autosomal Dominant Polycystic Kidney Disease (ADPKD). This study aims to optimize dosing and pharmacokinetics to support a Phase 2 proof-of-concept study expected in Q4 2026. SCY-770 has s", "url": "https://www.manilatimes.net/2026/06/30/tmt-newswire/globenewswire/scynexis-initiates-phase-1-study-of-scy-770-a-novel-ampk-activator-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd/2375739", "source_name": "The Manila Times", "published_at": "2026-06-30T12:09:58", "published_display": "30 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast for SCYNEXIS, Inc. (SCYX) stock, including analyst price targets and current financial data. It notes that three analysts have provided 1-year price forecasts, with estimates ranging from $24.00 to $44.64. The company's current stock price, market ", "url": "https://www.tradingview.com/symbols/NASDAQ-SCYX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-30T10:10:12", "published_display": "30 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of SCYNEXIS, Inc. \u2013 NASDAQ:SCYX", "summary": "This article provides financial data for SCYNEXIS, Inc. (NASDAQ: SCYX), specifically focusing on its price-to-sales forward metric. It details the stock's status as market closed with no trades and lists various services that provide market and reference data for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-SCYX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T07:41:02", "published_display": "30 Jun 2026 07:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of SCYNEXIS, Inc. \u2013 NASDAQ:SCYX", "summary": "The article provides a snapshot of SCYNEXIS, Inc. (NASDAQ: SCYX) on TradingView, focusing on its \"Price to book forward\" metric. It lists various sections available on the platform for the company, including financials, news, and technical analysis, but does not provide specific ", "url": "https://www.tradingview.com/symbols/NASDAQ-SCYX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T04:41:33", "published_display": "30 Jun 2026 04:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of SCYNEXIS, Inc. \u2013 GETTEX:135", "summary": "This article provides financial information for SCYNEXIS, Inc. (GETTEX:135), specifically focusing on its enterprise value to revenue forward metric. The data is presented within the context of the Gettex exchange and is sourced from various financial data providers.", "url": "https://www.tradingview.com/symbols/GETTEX-135/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T23:41:34", "published_display": "29 Jun 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of SCYNEXIS, Inc. \u2013 NASDAQ:SCYX", "summary": "The article displays the enterprise value to EBITDA forward for SCYNEXIS, Inc. (NASDAQ: SCYX) on the TradingView platform. It shows the stock information and indicates that the market is closed with no trades. The article is a snapshot from a financial platform, providing basic s", "url": "https://www.tradingview.com/symbols/NASDAQ-SCYX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T05:40:14", "published_display": "29 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of SCYNEXIS, Inc. \u2013 GETTEX:135", "summary": "The article focuses on the \"Price to sales forward\" metric for SCYNEXIS, Inc. (GETTEX:135). It appears to be a financial data point provided by TradingView, detailing a specific period, its value, and percentage change. The content itself seems to be a placeholder for financial d", "url": "https://www.tradingview.com/symbols/GETTEX-135/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T01:39:04", "published_display": "29 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS (SCYX) expands authorized stock and registers 87M shares for resale", "summary": "SCYNEXIS, Inc. (SCYX) has increased its authorized stock from 23,750,000 to 65,000,000 shares, with common stock specifically rising from 18,750,000 to 60,000,000 shares, following stockholder approval at its June 25, 2026 annual meeting. The company also registered up to 87,000,", "url": "https://www.stocktitan.net/sec-filings/SCYX/8-k-scynexis-inc-reports-material-event-663aabe53575.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:10:23", "published_display": "26 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS, Inc. Actuals & Estimates (NASDAQ:SCYX)", "summary": "This article provides a comprehensive overview of SCYNEXIS, Inc. (NASDAQ: SCYX), detailing its current stock price, historical performance, analyst forecasts, and financial data. It includes information on market capitalization, volatility, earnings reports, revenue, net income, ", "url": "https://www.tradingview.com/symbols/NASDAQ-SCYX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-24T10:10:46", "published_display": "24 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS Inc (SCYX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for SCYNEXIS Inc (SCYX), highlighting its current earnings forecast score, analyst ratings, and price targets. It notes an average price target of $4.00 and that analysts generally recommend a \"Buy\" trend for the stock, based on 3 analys", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scyx/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T12:09:53", "published_display": "18 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS Inc (SCYX) Institutional Confidence", "summary": "This article analyzes the institutional confidence in SCYNEXIS Inc (SCYX), reporting its current institutional shareholding score as 3.00, which ranks 94th out of 157 in the Pharmaceuticals industry. The institutional shareholding proportion is 25.24%, a 22.57% decrease quarter-o", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scyx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:10", "published_display": "18 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS Inc (SCYX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "SCYNEXIS Inc (SCYX) has a strong financial score of 9.27, ranking 5th in the Pharmaceuticals industry, indicating robust financial health and high operating efficiency. Despite this, its latest quarterly revenue saw a 100% year-over-year decrease, and net profit fell by 295.08%. ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scyx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:10", "published_display": "18 Jun 2026 10:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS Inc (SCYX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of SCYNEXIS Inc (SCYX), detailing its current stock price momentum, support and resistance levels, and insights from various technical indicators and moving averages. While the stock is currently trading within a range, technical signals", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scyx/technical", "source_name": "TradingKey", "published_at": "2026-06-18T09:40:09", "published_display": "18 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS Inc (SCYX) Valuation: PE, PB & Fair Value Analysis", "summary": "SCYNEXIS Inc (SCYX) currently holds a valuation score of 9.33, ranking 32nd out of 157 companies in the Pharmaceuticals industry. The company's P/E ratio is -7.89, which is significantly below its recent high but above its recent low. Key valuation metrics such as P/B, P/S, and P", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-scyx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T09:40:09", "published_display": "18 Jun 2026 09:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS Announces One-for-Eight Reverse Stock Split", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/scynexis-announces-one-eight-reverse-201500685.html", "source_name": "GlobeNewswire", "published_at": "2026-05-22T20:15:00+00:00", "published_display": "22 May 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS (SCYX) Announces 1-for-8 Reverse Stock Split to Meet Na", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxQVWNRSmk5MFVjMklNLW81aDkyM2tpejJxQV92TE9MQ3ByZzR4dFZ2dFFybFhOWW5hZmtmZDVFOTVNSEpLdDhTaERqbXNTaUViQml3eVpOMUFzNGdjZWZSUXJoakdrTUZvRXpub0RIcXZ2cHRoaC1OS1JlR2E0UE0yUk0yd3U5dUZnV3RBOUV6VWdrc1l2ODNHcGpTX19PLXRrVkVaT3M5ZHphdFBscGVsUmZjOHhzc254MlA1QklySlBnc3l6MnEyeTM4ZmE0d01LUzFiSG1JVlZHYXh2?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS announces 1-for-8 reverse stock split effective May 29", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQM2YxbzV3eWZEdGdoaHdxNi1MQnV0OGl4TWNMUkg1LTdHTy1OSHNuLVQ5WHBPd3dwSHNFYnBNd0V0R2EwMUYxUDNIbjdGejI2Qi1lVEJ2N3pieWc1ZmZ0NVlQc2liZHYyTGwtT1JmUm5oZlZxdW1DRTB1Y0hwRnVER0xackVaQ28yeFItbXhaNFlsNktxM3hscU10bnM0XzBIcmJOZU9FX3VWY1BIei1wUGIxRmptVElzQXc?oc=5", "source_name": "Investing.com", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scynexis stock falls 7% on reverse stock split announcement", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNZWtDWExId0RSWnhGT3hRS2FiNHJZYk10VlladFBrcG5xUmYwSGhieDlWdXBqNkpxd3hOTGlfT1BhOXprbFpWNjUyNlpxeVUwZVotR0l1MllRY3Y0QU1idVJ3U3U4MG5vbTJ2UmRwVEE3M1IwUXZZYnRFRGNmNWVDTEFhVFp5R3Q2dWd0YlM1Z0JUTTFad1ZEVG5WYUlrdVFSUEt0MXE3bHI5OTlBWl9Ib2FjOWx6R19oV0c4Sw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scynexis: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/scynexis-q1-earnings-snapshot-204354134.html", "source_name": "Associated Press", "published_at": "2026-05-11T20:43:54+00:00", "published_display": "11 May 2026 20:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/scynexis-reports-first-quarter-2026-202300240.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T20:23:00+00:00", "published_display": "11 May 2026 20:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/scynexis-announces-inducement-awards-under-011500593.html", "source_name": "GlobeNewswire", "published_at": "2026-05-07T01:15:00+00:00", "published_display": "07 May 2026 01:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scynexis CEO Angulo Gonzalez buys $100k in shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQcnZlZUhFeFZ5YkgzM0pYNzhvSmFNWTJJWTUwQmVXSnV4ZzhyTEpoRy1hRTRqaFNyQkdObk1zMmR5elVpZWhWNUFGNG9ZSzFhMDNRdTZKdHlFS2JiX0xCTHU1OHBXdF9aTVFDUzVia1pqa2NlSFdOOXlXVFRDYWpmWnV2N0o1U1VKTlpaN0UteEd0bXZLR2l0QlczVzJlRTJKUnhvdTNocjBCMmYxUnA1VmFjaw?oc=5", "source_name": "Investing.com", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scynexis In Spotlight After Poxel Deal, $40 Million Private Placement \u2013 SCYX Stock Climbs 2% Pre-Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQWWhpTzBqRF9WeWZZYUt1Sy0tVXlUakRtM2ZiTHhNWDhvTVRIaGtlWDQyTnQyalJRYnJ2Z2MxNWM0OFFiVExodU9XMjRHdUZyRS1hSDQwWE01ckhrUDFiWG9zaG5XazdrSGs5R3djWHVnaGJ3bG9EV1NhZkVucndjZ3BGMDlUeklrLVJkdmdGMWkzSzdjM0lMcGgybjI2NU5YR0NrellZa3dKT0U?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS acquires SCY-770 for rare kidney disease treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNd0RMN2dsOEZhU1hNOTgxenhQV0NMNUVuNXVPcHM1LWtoUWxDVzVtNzh1Q2JBc1pUa0dad2ZiNHRZWXBWYlA2b0VaQ2V6eFN5Q0JPUXdmdWxqX2Vlcmpwa0xuNWZON1NjNktVdmxMQnhHdEVhYVNTMlE5VUpEVDlrTFZmczF0dmJhRHZtUFB5NlFmb0RHVlVBVkV1N1lEVFJNTDRBX2dTZUtIQ0RNc1hsQWkzNExRQQ?oc=5", "source_name": "Investing.com", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS Completes BREXAFEMME NDA Transfer to GSK, Positioning for Future Milestones and Royalties", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxQTWRMVnZRQXpxNEx1ZEgwR25MWm5RemUxSVJQMloxaVBvRU5yRHdFblJrNVBNTFZudW1jNnE4U0tPUWNxb3g4WlhSLUtBVTd5c0YzeHBNMndEQVhycVBEeGNneTRLazlmczFzc3RiN2R2alFpY3FSTS12b2FERWQxVkRfNXJEaXdLSWtTVnNIQ1pmMkJCVm1kbUVSY2RhRUZZLXZCdHE0SFBuVFRoQVF3cHBOT1AzUFdEbk9sdU9mYkU5UzhQS1pRTm96aEpMUQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-11-19T08:00:00+00:00", "published_display": "19 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're A Bit Worried About SCYNEXIS' (NASDAQ:SCYX) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE5oQUg0d1gzQnhiRm5LZjVWZENVVEMyckFySjlFQUFHUk5mYWhJN01XMEM1TFhsUEpnZHE5bVNxQzRQQlFpbE4yc1RDSVN6dGpDdDR2bzJyenByMlFBWk9CZXRqRFV6UTBkbVFYNzVCdVBmMlJXWjZ3U21sQjM?oc=5", "source_name": "Market source", "published_at": "2025-11-10T08:00:00+00:00", "published_display": "10 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS Secures $24.8 Million Payment from GSK and Advances SCY-247 Development Plans Amid Phase 3 Study Termination", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOY0UxRFRyVm1wRTMwWk4zOXFibVBhZmpDaVp3WVNEQzZwbXFWR2xzV19VV3NNVXlHWnRRcjJtUk1vUC1qcnBuUGNYWkhvQjRlVXBlazlQRVV0aTZhWDY2RFJ3X01nTktPX0VrZm1Ienk5V196aXpnbFV2aDZRRHZVQnA5RG5WWV9yVlp4WkJzb080bk5fMEU0cDkydzZpcnR4NkNCRERCdzZXWWZMTUIzREZ5T2ZkQTdfLUZ4Y3l0MXpMWkRxWE84UEdNQkVRUDRLYUdidHNPb3E4Zjk0a0VGTWFVTGFkRms?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-11-05T08:00:00+00:00", "published_display": "05 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYX Stock Price and Chart \u2014 NASDAQ:SCYX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE1wbnRQcXhNUE84U0pLV2lGZ3hJbkNqUzBnYi1meUdfWVRpUFp0SkZ4ejV5dWs5SmhZSnllZ1k0NGM4ckVQQlFLXy1nbmVoQXRINzRaNWp4SFptQnFt?oc=5", "source_name": "TradingView", "published_at": "2017-07-21T03:30:44+00:00", "published_display": "21 Jul 2017 03:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SCYNEXIS (SCYX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1WYWZ5RE1ERFAxcVpib01XNUdpZE54VjItR1lwSWNTYzRMOV9jaWJhOHlGWnlsdGlRREJ2MnJCSExYNzU1TTd6QnEwSmNPbDFxRmtlYkxMNmhXZw?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-12T07:14:17+00:00", "published_display": "12 Aug 2016 07:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 74, "total_relevant": 43, "sentiment_summary": {"positive": 3, "negative": 5, "neutral": 35, "score": 50, "total": 43, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 15.95, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 4.2, "count": 7}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 3, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 4.38, "latest_week": "2026-07-10", "one_week_move": -1.1, "four_week_move": 3.5, "twelve_week_move": -50.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.183215, "market_dynamics_buy_signal": false, "relative_strength": -39.11761, "fair_value_gap": -59.7, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 39.1267, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.1% over one week, +3.5% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 59, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 11}, {"label": "Stock Titan", "count": 7}, {"label": "TradingKey", "count": 5}, {"label": "Investing.com", "count": 4}, {"label": "GlobeNewswire", "count": 3}, {"label": "GuruFocus", "count": 2}, {"label": "Investing.com Nigeria", "count": 2}, {"label": "Quiver Quantitative", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 43}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 7}, {"label": "Deals and strategy", "count": 2}, {"label": "Regulatory and legal", "count": 2}, {"label": "Balance sheet", "count": 2}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "43", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-1.1% over one week, +3.5% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "FEDERATED HERMES, INC. Acquires 55,207 Shares of SCYNEXIS Inc"}], "updated_at": "2026-07-17T23:54:11.119476+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}